Fermer définitivement
Fermer le menu

 

 

 

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

 

 

 

  • The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today.
  • The DSMB recommended that the study continue as planned.
  • MaaT033 continues to demonstrate a favorable safety profile and tolerability.

 

 

Read the press release

Plus d'infos